Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Accumulated Expenses: 2022-2025

Historic Other Accumulated Expenses for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $749,000.

  • Taysha Gene Therapies' Other Accumulated Expenses fell 14.50% to $749,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $749,000, marking a year-over-year decrease of 14.50%. This contributed to the annual value of $752,000 for FY2024, which is 4.01% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Other Accumulated Expenses is $749,000, which was down 6.38% from $800,000 recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Other Accumulated Expenses peaked at $1.6 million during Q1 2022, and registered a low of $650,000 during Q4 2022.
  • For the 3-year period, Taysha Gene Therapies' Other Accumulated Expenses averaged around $756,273, with its median value being $752,000 (2024).
  • As far as peak fluctuations go, Taysha Gene Therapies' Other Accumulated Expenses crashed by 56.90% in 2023, and later rose by 28.63% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Other Accumulated Expenses (Quarterly) stood at $650,000 in 2022, then climbed by 11.23% to $723,000 in 2023, then grew by 4.01% to $752,000 in 2024, then declined by 14.50% to $749,000 in 2025.
  • Its Other Accumulated Expenses stands at $749,000 for Q3 2025, versus $800,000 for Q2 2025 and $806,000 for Q1 2025.